DRUG INFORMATION ALERT
|
|
- May Russell
- 5 years ago
- Views:
Transcription
1 Paul Davis From: Sent: To: Subject: TSHP Friday, December 20, :03 AM Drug Info Alert - Unseen Danger: Dust-Born Disease DRUG INFORMATION ALERT December 20, 2013 Unseen Danger: Dust-Born Disease Katherine Kelly, PharmD Intern and Jennifer K Seltzer, PharmD Coccidioidomycosis, or valley fever, is a fungal disease observed primarily in the southwestern United States. 1 The majority of disease cases are reported in Arizona and California, but endemic areas include Texas, Nevada, Utah, New Mexico, Mexico, Central and South America. While south Texas is considered an endemic area, the Texas Department of State Health Services does not classify coccidioidomycosis as a notifiable condition, and thus disease rates are underreported. 2-4 The prevalence of valley fever has been increasing over the last several decades. In 2011, over 20,000 cases were reported (double that of tuberculosis), and it is estimated that more than 150,000 cases may be undiagnosed annually. 1 Coccidioidomycosis is not ordinarily transmitted from person to person or animals to persons, even though the animal population is affected as well. 1,4 Coccidioidomycosis is not a threat to a majority of those exposed, but 40% of cases include hospitalizations and complications. 2 Severe coccidioidomycosis cases can develop into chronic pulmonary disease, osteomyelitis, or meningitis. 1 Additionally, the common symptoms and presentation of coccidioidomycosis complicate diagnosis and differentiation from other conditions like influenza, leading to further underdiagnosis. 2 Healthcare provider awareness of the disease is a key factor in prompt diagnosis and treatment to prevent complications. 1,2 Coccidioidomycosis comes from the soil fungi, Coccidioides immitis and Coccidioides posadasii, which live in arid, low rainfall areas. 1 People who reside in endemic areas or travel to these areas can be exposed to the fungus by inhaling Coccidioides arthroconidia (spores). 1 Gautam et al. 4, using serologic data from dogs across Texas, determined the high endemic areas are the western and south-western regions of the state. Common risk factors for exposure are displayed in Table 1. 1,5 Once Coccidioides arthroconidia are inhaled, the temperature and environment of the lungs enable them to develop into a spherule. The spherules divide internally until they are filled with endospores and grow so large that the spherule bursts, releasing endospores into the surrounding tissue. 1 These endospores 1
2 can develop into additional spherules and can migrate to different parts of the body, including the joints, bones, skin, and central nervous system. 5 Table 1. Risk Factors for Coccidioides Exposure 1,5 Living in an endemic area (California, New Mexico, Arizona, Texas, Utah, Nevada)* History of travel to an endemic area Yard work, gardening, digging Working in a dusty environment, such as a construction zone Agricultural workers Miners Archaeologists Military personnel performing training exercises in an endemic area Dirt biking or other outdoor recreational activities that might cause dust inhalation being in an endemic area during a drought, dust storm, earthquake, or other natural disaster *Has also been reported in: Delaware, Louisiana, Maryland, Michigan, Minnesota, Missouri, New Hampshire, Ohio, Rhode Island, and Wyoming An estimated 30%-60% of people in endemic areas are exposed to the fungus at some time in their lives. 1 About 60% of exposed people are asymptomatic, while the other 40% have symptoms that range in severity, some requiring hospitalization. 5 Commonly reported symptoms, listed in Table 2, generally last longer than a week. 5,6 These symptoms are nondescript and are associated with a variety of other medical conditions, which can lead to underdiagnosis and delayed treatment. Table 2. Common Symptoms of Coccidioidomycosis 5,6 Fever Chills Cough Headache Rash- trunk or extremities o Erythema nodosum o Erythema multiforme Myalgias Arthralgias Shortness of breath Malaise Night Sweats Weight Loss In cases of severe disease, patients may develop chronic pulmonary infections or have the fungus disseminate to other parts of the body. 1 Population groups at risk for having severe disease are listed in Table 3. 5 Table 3. High-Risk Populations for Severe or Disseminated Coccidioidomycosis 5,7 Elderly HIV-infected individuals with CD4 count less than 200/μL Pregnant women in the third trimester People receiving steroids or immune-compromising agents, like tumor necrosis factoralpha (TNF-α) inhibitor therapy Smokers Other immunocompromising conditions (e.g., diabetes, chronic pulmonary disease, chronic renal failure, congestive heart failure) African Americans Asians Filipinos 2
3 Solid Organ Transplant Patients HIV = Human Immunodeficiency Virus Since symptoms are indistinguishable from other viral or bacterial infections, about 30% of coccidioidomycosis infections are misdiagnosed as bacterial community-acquired pneumonia. 1,7,8 Routine tests may show nonspecific results, such as increased white blood count, peripheral eosinophilia, and elevated erythrocyte sedimentation rate. 9 Chest x-rays or CT scans of the lungs can be used to investigate signs of infiltration of Coccidioides, but distinguishing the pathogen from others based on radiograph alone is difficult. 1 Tests for coccidioidomycosis should be considered in endemic areas and especially when treatment for bacterial infections fails. 7 Although Coccidioides readily grows on culture media within seven days, culturing the organism poses a high risk to laboratory workers and should be handled using Biosafety Level 3 containment. 8 IgM and IgG enzyme immunoassays (EIA) are the most sensitive serologic assay, while immunodiffusion tests are the most specific serologic assay for Coccidioides. 8,9 EIA tests may be used in combination with immunodiffusion tests when confirmation is needed.8,9 Both the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) have published guidelines for management of coccidioidomycosis and have made similar recommendations. Treatment is based on disease manifestation and patient immune system status. Treatment options include azole antifungals and amphotericin B. Table 4 summarizes the ATS recommendations for managing different coccidioidomycosis manifestations. 7 Table 4. ATS Coccidioidomycosis Treatment Recommendations 7 Primary Pulmonary Diseases No therapy for most patients If patient has risk factors for disseminated disease (listed in Table 3) or has had infection for >6 weeks, consider standard therapy* for 3-6 months or longer Follow-up should last a year to assure complete resolution Persistent Pulmonary Diseases Nodules No treatment for nonimmunocompromised patients Consider standard therapy* for periods of significant immunosuppression in compromised individuals Cavities No treatment for nonimmunocompromised patients Consider standard therapy* for: o 3-6 months in patients with severe symptoms(pleuritic chest pain, productive cough, or hemoptysis) o months in immunocompromised individuals o Could treat for longer or until cavity/symptoms stabilize Diffuse Pulmonary Amphotericin B treatment** until clinical improvement, followed by standard therapy* for at least a year For those with ongoing immune suppression, consider long-term maintenance with an azole Disseminated Disease 3
4 Non-Meningeal Standard therapy* for at least a year and until clinical stabilization In severe cases amphotericin B treatment** until clinical improvement, followed by standard treatment* for at least another year Meningeal Lumbar puncture for any patients presenting with meningitis symptoms High dose fluconazole ( mg/d) or itraconazole ( mg/d) for life Intrathecal amphotericin B may be required in some severe cases, when azoles fail, or when rapid response is desired Experts should be consulted in managing coccidioidal meningitis *Standard Therapy: 400 mg/day orally of fluconazole or itraconazole **Intravenous liposomal amphotericin B (5 mg/kg/day) or ampotericin B ( mg/kg/day) There are few clinical trials assessing antimicrobial treatment for valley fever. Compared to conventional amphotericin B, liposomal amphotericin B has not demonstrated greater efficacy in treating coccidioidomycosis but has shown reductions in renal and other toxicities. 7 Additionally, investigators evaluated fluconazole and itraconazole efficacy for non-meningeal coccidioidomycosis in a randomized, double-blind trial and found no significant differences between treatment groups. Itraconazole, however, did show a significant benefit in patients with bone infections following 12 months of therapy but not at 8 months. 11 Therefore, ATS guidelines suggest that itraconazole may be preferred in patients with disseminated infection in the bones and joints. 7 Some smaller studies and case reports suggest that posaconazole or voriconazole may be beneficial in patients with severe or refractory disease. 7,11-15 Nikkomycin Z is an antifungal agent that inhibits the enzyme that makes chitin, a fungal cell wall component. 16 This orphan drug is being studied at the University of Arizona, where phase 1 trials have been completed. 16,17 However, due to lack of funding, a phase 2 study was terminated early. 17 Researchers hope to gain enough funding to restart clinical trials with this promising agent. 16 Research to develop a vaccine for valley fever is also being conducted. 1,18 Since Coccidioides spores are airborne, coccidioidomycosis is a difficult disease to prevent. Wearing safety masks and avoiding dusty environments may provide some protection to high-risk individuals. 1 Recognition and awareness in endemic areas could lead to prompt diagnosis and treatment of severe cases before the disease disseminates. Texas healthcare professionals and populations living in west or southwest Texas should be aware of risk factors and potential complications from this fungus. Future research involves studying weather patterns that affect the fungus, epidemiology trends across the United States, and better treatment options. 1 References 1. Centers for Disease Control and Prevention. Coccidioidomycosis (Valley Fever). Available at: Accessed November 18, Centers for Disease Control and Prevention. Increase in reported coccidioidomycosis--united States, MMWR Morb Mortal Wkly Rep. 2013;62:(12): Texas Department of State Health Services. Notifiable conditions list. Available at: Accessed November 19, Gautam R, Srinath I, Clavijo A, et al. Identifying Areas of High Risk of Human Exposure to Coccidioidomycosis in Texas Using Serology Data from Dogs. Zoonoses Public Health. 2013;60:(2): Chiller, T. Coccidioidomycosis. Centers for Disease Control and Prevention. Available at: Accessed November 19, California Department of Public Health Division of Communicable Disease Control. Quick tips on 4
5 coccidioidomycosis (valley fever) for healthcare providers. Available at: Accessed November 19, Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183:(1): Ampel NM. The diagnosis of coccidioidomycosis. F1000 Med Rep. 2010;2. 9. Galgiani, JN. Laboratory diagnosis of coccidioidomycosis. In: UpToDate, Kauffman, CA (Ed), UpToDate, Waltham, MA, Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis. 2005;41:(9): Anstead GM, Corcoran G, Lewis J, et al. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis. 2005;40:(12): Stevens DA, Rendon A, Gaona-Flores V, et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest. 2007;132:(3): Catanzaro A, Cloud GA, Stevens DA, et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis. 2007;45:(5): Kim MM, Vikram HR, Kusne S, et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis. 2011;53:(11): Cortez KJ, Walsh TJ, Bennett JE. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis. 2003;36:(12): Galgiani, JN. The Search for the Cure for Valley Fever Nikkomycin Z Development at the University of Arizona. Available at: Accessed November 21, ClinicalTrials.gov. Available at: Accessed: November 21, Cole GT, Hurtgen BJ, Hung CY. Progress toward a human vaccine against coccidioidomycosis. Curr Fungal Infect Rep. 2012;6:(4): Forward this This was sent to paul.davis@tshp.org by paul.davis@tshp.org Update Profile/ Address Instant removal with SafeUnsubscribe Privacy Policy. TSHP 3000 Joe DiMaggio #30A Round Rock TX
Coccidioidomycosis, aka Valley Fever
Coccidioidomycosis, aka Valley Fever Presented to the California Partnership for the San Joaquin Valley June 15, 2018 Karen Haught, MD, MPH Public Health Officer Tulare County Public Health Coccidioidomycosis
More informationOverview of Coccidioidomycosis (Valley Fever) Stephen Munday, MD MPH Imperial County Public Health May 21, 2013
Overview of Coccidioidomycosis (Valley Fever) Stephen Munday, MD MPH Imperial County Public Health May 21, 2013 Objectives Assess the epidemiology of Coccidioidomycosis (aka Valley Fever) Describe the
More informationCalifornia digging. Task 1 Interpret the chest radiograph. L. Hendriks
Case history An18-yr-old male presented at the emergency department with a 4-week history of fever, coughing and dyspnoea. Symptoms presented on a holiday in California (USA) searching the desert for fossils.
More information3/16/16 COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS. Selected References
10 MARCH 2006 Updated 5 June 2008 Updated 11 February 2011 Updated 4 March 2016 Herbert Boro, M.D., F.A.C.P. Selected References 1. Fiese, Marshall J. 1958. Coccidioidomycosis. Charles C. Thomas. 253 pp.
More informationTitle: Public Health Reporting and National Notification for Coccidioidomycosis
10-ID-04 Committee: Infectious Diseases Title: Public Health Reporting and National Notification for Coccidioidomycosis I. Statement of the Problem: In 1994, CSTE passed a resolution recommending key federal
More informationCoping with Valley Fever Information for Families
Coping with Valley Fever Information for Families Valley Children s Healthcare & University of California, Merced 9300 Valley Children s Place Madera, CA 93636 Social Worker: Margie Arreguin-Zarate, LCSW
More informationCOCCIDIOIDES SPP. EXPOSURE/INJURY RESPONSE PROTOCOL
PLEASE POST THIS PAGE IN AREAS WHERE COCCIDIOIDES IS USED IN RESEARCH LABORATORIES UNIVERSITY OF CALIFORNIA, SAN FRANCISCO ENVIRONMENTAL HEALTH AND SAFETY/BIOSAFETY COCCIDIOIDES SPP. EXPOSURE/INJURY RESPONSE
More informationTreatment of Coccidioidomycosis-associated Eosinophilic Pneumonia with Corticosteroids
Treatment of Coccidioidomycosis-associated Eosinophilic Pneumonia with Corticosteroids Joshua Malo, MD Yuval Raz, MD Linda Snyder, MD Kenneth Knox, MD University of Arizona Medical Center Department of
More informationCoccidioidomycosis Update for Primary Care
Coccidioidomycosis Update for Primary Care SW Conference on Medicine April 26, 2018 John N Galgiani MD University of Arizona What Is? Caused by soil fungi Coccidioides immitis Coccidioides posadasii Other
More informationIncidence rate per 100,000 persons Year FIGURE 1. The incidence of coccidioidal infection in
Coccidioidomycosis CONCISE REVIEW FOR COCCIDIOIDAL CLINICIANS INFECTION JAMES M. PARISH, MD, AND JANIS E. BLAIR, MD On completion of this article, you should be able to (1) describe the geographic areas
More informationDisseminated Coccidioidomycosis of the Rearfoot: A case report
Open Access Publication Disseminated Coccidioidomycosis of the Rearfoot: A case report by Robert Frykberg, DPM, MPH 1 4 Tierney, DPM 2 3, Beth Noe, DPM, Stephanie Michael, DPM, Edward The Foot & Ankle
More informationISPUB.COM. Coccidioidomycosis In A Cancer Hospital. A Huaringa INTRODUCTION
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 11 Number 2 Coccidioidomycosis In A Cancer Hospital A Huaringa Citation A Huaringa. Coccidioidomycosis In A Cancer Hospital. The Internet Journal
More informationMike Olbinski. Mike Olbinski. Michael Olbinski
Mike Olbinski Mike Olbinski Michael Olbinski Table of Contents List of Figures and Tables... 3 Executive Summary... 4 Introduction... 5 Epidemiology in Arizona... 7 Reporting Sources and Changes in Laboratory
More informationJohn Galgiani MD or Fariba Donovan MD PhD Banner University Valley Fever Program
John Galgiani MD or Fariba Donovan MD PhD Banner University Valley Fever Program Drs. Galgiani and Donovan Have no conflicts of interest to disclose Caused by soil fungi Coccidioides immitis Coccidioides
More informationGuidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification
More informationManagement of Coccidioidomycosis in Rheumatic Patients on Biologic Response Modifiers
Management of Coccidioidomycosis in Rheumatic Patients on Biologic Response Modifiers Dominick George Sudano, MD Assistant Professor of Medicine Department of Rheumatology University of Arizona Objectives
More informationTeenage Female With Chronic Coccidioidomycosis and Left Wrist Pain
http://www.hcplive.com/journals/family practice recertification/2015/may2015/teenage Female With Chronic Coccidioidomycosis and Left Wrist Pain Teenage Female With Chronic Coccidioidomycosis and Left Wrist
More informationCoccidioidomycosis in Infants: A Retrospective Case Series
Coccidioidomycosis in Infants: A Retrospective Case Series Jessica M. Lee, MD, 1,2 * Ana Lia Graciano, MD, 1,3 Lukasz Dabrowski, MD, 1,4 Brenik Kuzmic, PharmD, 5 and Mary Anne Tablizo, MD 1,6 Summary.
More informationA horrible, painful disease
October 17, 2016 House Majority Leader Kevin McCarthy Phoenix, UA Med School - Arizona Republic - Tucson Arizona Star A horrible, painful disease Raising the Standard of Care David Larwood, MS/JD/MBA,
More informationFungal Diseases of the Respiratory System
Fungal Diseases of the Respiratory System Histoplasmosis(cave disease) Dr. Hala Al Daghistani Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. Histoplasma capsulatum, is usually
More informationNorth American Endemic Fungi
North American Endemic Fungi Boni Elizabeth Elewski, MD Chair Department of Dermatology University of Alabama at Birmingham James Elder Professor of Graduate Medical Education DISCLOSURE OF FINANCIAL RELATIONSHIPS
More informationHistoplasmosis. Disease Etiology: Disease Transmission: Reservoirs: Specific Microbial Characteristics: By: Ernest Aguilar
Histoplasmosis By: Ernest Aguilar Disease Etiology: Histoplasmosis is an infection resulting from the inhalation of spores belonging to the fungus Histoplasma capsulatum. [1] This one of three fungi that
More informationCoccidioidal Meningitis in Kings County A Public Health Perspective
Coccidioidal Meningitis in Kings County A Public Health Perspective Michael L Mac Lean, M.D., M.S. Health Officer, Kings County, California December 1, 2011 Introduction It is particularly important to
More informationFungal Infections. Fungal Infections
Fungal Infection in the Immune Competent Host Steven L. Primack, MD Fungal Infection in the Immune Competent Host Steven L. Primack, MD Department of Radiology Oregon Health & Science University Fungal
More informationLecture 7: Mycoses Caused by Dimorphic Fungi, Part I
BIOL 4849 Medical Mycology Summer 2006 Histoplasmosis Lecture 7: Mycoses Caused by Dimorphic Fungi, Part I u Most common endemic mycotic disease in the United States u Two different varieties (actually
More informationCommon Fungi. Catherine Diamond MD MPH
Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold
More information2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
Clinical Infectious Clinical Diseases Infectious Diseases Advance Access published July 27, 2016 IDSA GUIDELINE 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment
More informationDisseminated coccidioidomycosis in an AIDS patient presented with nasal mass
Case Report Vol. 29 No. 2 Disseminated coccidioidomycosis in an AIDS patient presented with nasal mass:-senran K, et al. 75 Disseminated coccidioidomycosis in an AIDS patient presented with nasal mass
More informationAlberta Health and Wellness Public Health Disease Under Surveillance Management Guidelines March 2011
March 2011 Histoplasmosis Case Definition Confirmed Case Clinical illness [1] with laboratory confirmation of infection: Isolation of Histoplasma capsulatum from an appropriate clinical specimen (tissue
More informationRoyce Johnson, M.D., F.A.C.P. Disclosure Information Research Support/Consultant/Speaker
Royce Johnson, M.D., F.A.C.P. Disclosure Information Research Support/Consultant/Speaker Astellas Enzon Pharmaceuticals Merck & Co, Inc. Ortho-McNeil, Inc. Pfizer, Inc. Sanofi Aventis Schering-Plough The
More informationCoccidioidomycosis IDSA GUIDELINES EXECUTIVE SUMMARY INTRODUCTION
IDSA GUIDELINES Coccidioidomycosis John N. Galgiani, 1,2,3 Neil M. Ampel, 1,2,3 Janis E. Blair, 4 Antonino Catanzaro, 5 Royce H. Johnson, 6 David A. Stevens, 7,8 and Paul L. Williams 9 1 Valley Fever Center
More informationTreatment of Pediatric Refractory Coccidioidomycosis With Combination Voriconazole and Caspofungin: A Retrospective Case Series
MAJOR ARTICLE Treatment of Pediatric Refractory Coccidioidomycosis With Combination Voriconazole and Caspofungin: A Retrospective Case Series Emily R. Levy, 1 James M. McCarty, 2,3 Andi L. Shane, 4 and
More informationPractice Guidelines for the Management of Patients with Blastomycosis
679 Practice Guidelines for the Management of Patients with Blastomycosis Stanley W. Chapman, 1 Robert W. Bradsher, Jr., 2 G. Douglas Campbell, Jr., 3 Peter G. Pappas, 4 and Carol A. Kauffman 5 From the
More informationPrecision Health in Valley Fever Does Ancestry Matter? John N Galgiani MD Valley Fever Center for Excellence University of Arizona
Precision Health in Does Ancestry Matter? John N Galgiani MD University of Arizona Coccidioidomycosis Spectrum of Disease 100 Infections 60 No Symptoms 40 Symptoms 37 Recover Life-Long Immunity 100,000-
More informationEarly Treatment With Fluconazole May Abrogate the Development of IgG Antibodies in Coccidioidomycosis
MAJOR ARTICLE Early Treatment With Fluconazole May Abrogate the Development of IgG Antibodies in Coccidioidomycosis George R. Thompson III, 1,2 Jennine M. Lunetta, 1 Suzanne M. Johnson, 1 Sandra Taylor,
More informationCalifornia Association for Medical Laboratory Technology
California Association for Medical Laboratory Technology Distance Learning Program COCCIDIOIDOMYCOSIS (VALLEY FEVER): A REEMERGING MYCOSIS Course # DL-993 by Lucy Treagan, Ph.D. Prof. Biology, Emerita
More informationThe Public Health Impact of Coccidioidomycosis in Arizona and California
Int. J. Environ. Res. Public Health 2011, 8, 1150-1173; doi:10.3390/ijerph8041150 OPEN ACCESS Article International Journal of Environmental Research and Public Health ISSN 1660-4601 www.mdpi.com/journal/ijerph
More information-Type of immunity that is more permanent (WBC can Remember)
-Type of immunity that is more permanent (WBC can Remember).Get disease- Your body produces its own antibodies (killer T cells) to attack a particular pathogen 2.Vaccination- Injection containing a dead
More informationCoccidioidomycosis, also called, is caused
REVIEW Coccidioidomycosis in African Americans Barbara E. Ruddy, MD; Anita P. Mayer, MD; Marcia G. Ko, MD; Helene R. Labonte, DO; Jill A. Borovansky, MD; Erika S. Boroff, MD; and Janis E. Blair, MD Coccidioidomycosis
More informationINFECTIOUS DISEASE San Luis Obispo County 47 photo credit: Tara Kennon
San photo Luis credit: Obispo Tara County Kennon 47 Good News Spotlight Immunization Rates: Laws Can Make a Difference In 2016, a state law (SB277) eliminated the personal belief exemption from vaccine
More informationCase 1. Background. Presenting Symptoms. Schecter Case1 Differential Diagnosis of TB 1
TB or Not TB? Case 1 Gisela Schecter, M.D., M.P.H. California Department of Public Health Background 26 year old African American male Born and raised in Bay Area of California Convicted of cocaine trafficking
More informationSpecificity of Enzyme Immunoassay for Serologic Coccidioidomycosis Diagnosis Compared to Immunodiffusion
Specificity of Enzyme Immunoassay for Serologic Coccidioidomycosis Diagnosis Compared to Immunodiffusion Item Type Thesis Authors Petein, Nathalie Rights Copyright is held by the author. Digital access
More informationLyme Disease Surveillance in Wisconsin Christopher Steward Division of Public Health Wisconsin Department of Health Services 04/10/2014
Lyme Disease Surveillance in Wisconsin Christopher Steward Division of Public Health Wisconsin Department of Health Services 04/10/2014 Protecting and promoting the health and safety of the people of Wisconsin
More informationGAFFI Fact Sheet. Disseminated histoplasmosis
F GAFFI Fact Sheet Disseminated histoplasmosis ION NS ACT ALOR ECTIO B O F F L G ND L IN FU NGA FU Disseminated histoplasmosis is a sub- acute infection that may be diagnosed in patients with impaired
More informationSurgery for Pulmonary Coccidioidomycosis: A 10-Year Experience
Surgery for Pulmonary Coccidioidomycosis: A 10-Year Experience Dawn E. Jaroszewski, MD, Wissam J. Halabi, MD, Janis E. Blair, MD, Brandon J. Coakley, BS, Raymond K. Wong, PhD, CCP, James M. Parish, MD,
More informationCoccidioidomycosis in Patients with Diabetes Mellitus
The American Journal of Medicine (2006) 119, 964-969 CLINICAL RESEARCH STUDY AJM Theme Issue: Infectious Disease Coccidioidomycosis in Patients with Diabetes Mellitus Ana C. Santelli, MD, a Janis E. Blair,
More informationCOHORT STUDY OF HIV POSITIVE AND HIV NEGATIVE TUBERCULOSIS in PENANG HOSPITAL: COMPARISON OF CLINICAL MANIFESTATIONS
COHORT STUDY OF HIV POSITIVE AND HIV NEGATIVE TUBERCULOSIS in PENANG HOSPITAL: COMPARISON OF CLINICAL MANIFESTATIONS Ong CK 1, Tan WC 2, Leong KN 2, Abdul Razak M 1, Chow TS 2 1 Respiratory Unit, Penang
More informationSELECTED INFECTIONS ACQUIRED DURING TRAVELLING IN NORTH AMERICA. Lin Li, MD August, 2012
SELECTED INFECTIONS ACQUIRED DURING TRAVELLING IN NORTH AMERICA Lin Li, MD August, 2012 Case 1 32 year old male working in Arizona; on leave back in Singapore Presented to hospital A for fever x (7-10)
More informationCoccidioidomycosis: DISCLOSURES. Key Questions. Coccidioides: Life Cycle. Epidemiology. Origin of Coccidioides spp? 3/25/2018
Coccidioidomycosis: Recent Advances and Remaining Problems DISCLOSURES Name of Organization Relationship George R. Thompson III, MD, FIDSA Associate Professor Division of Infectious Diseases Department
More informationCase Report Coccidioides immitis Cervical Lymphadenitis Complicated by Esophageal Fistula
Case Reports in Infectious Diseases Volume 2016, Article ID 8715405, 4 pages http://dx.doi.org/10.1155/2016/8715405 Case Report Coccidioides immitis Cervical Lymphadenitis Complicated by Esophageal Fistula
More information2012 Medicaid and Partnership Chart
2012 Medicaid and Chart or Alabama $525,000.00 $4,800.00 Minimum: 25,000.00 Alaska $525,000.00 Depends on area of state; Minimum: $113,640 $10,000 in Anchorage $1,656 Minimum:$1838.75 Maximum:$2,841 Minimum:
More informationOCCCUPATIONAL COCCIDIOIDOMYCOSIS TWO CASE STUDIES. Mark Nicas, PhD, CIH School of Public Health University of California, Berkeley
OCCCUPATIONAL COCCIDIOIDOMYCOSIS TWO CASE STUDIES Mark Nicas, PhD, CIH School of Public Health University of California, Berkeley VALLEY FEVER = COCCIDIOIDOMYCOSIS Infection in lungs from inhaled Coccidioides
More informationPulmonary Coccidioidomycosis
Pulmonary Coccidioidomycosis Irene M. Spinello, M.D., 1 Augustine Munoz, M.D., 1 and Royce H. Johnson, M.D. 1 ABSTRACT Coccidioidal infection can manifest as pulmonary or extrapulmonary disease. Pulmonary
More informationThe Return of Delayed-Type Hypersensitivity Skin Testing for Coccidioidomycosis
REVIEW ARTICLE The Return of Delayed-Type Hypersensitivity Skin Testing for Coccidioidomycosis Elizabeth E. Wack, 1 Neil M. Ampel, 2,3 Rebecca H. Sunenshine, 4,5 and John N. Galgiani 1,2 1 Valley Fever
More informationCryptococcus gattii Fungal Meningitis. By Cassy Hedberg BI 234
Cryptococcus gattii Fungal Meningitis By Cassy Hedberg BI 234 This disease s deadliest weapon is the fact you ve never heard of it -Kausik Datta, Post-doctoral Fellow at Johns Hopkins Medicine A deadly
More informationECMM Excellence Centers Quality Audit
ECMM Excellence Centers Quality Audit Person in charge: Department: Head of Department: Laboratory is accredited according to ISO 15189 (Medical Laboratories Requirements for quality and competence) Inspected
More informationIP Lab Webinar 8/23/2012
2 What Infection Preventionists need to know about the Laboratory Anne Maher, MS, M(ASCP), CIC Richard VanEnk PhD, CIC 1 Objectives Describe what the laboratory can do for you; common laboratory tests
More informationHistoplasma, Coccidioides, Aspergillus, Other Systemic Fungal Pathogens And Paragonimus westermani
Histoplasma, Coccidioides, Aspergillus, Other Systemic Fungal Pathogens And Paragonimus westermani Dr. Sameer Naji, MB, BCh, PhD (UK) Dept. of Basic Medical Sciences Faculty of Medicine The Hashemite University
More informationChapter 18. Fungal Diseases of the Lung. Mosby items and derived items 2011, 2006 by Mosby, Inc., an affiliate of Elsevier Inc.
Chapter 18 Fungal Diseases of the Lung 1 YLS S M AC Figure 18-1. Fungal disease of the lung. Cross-sectional view of alveoli infected with Histoplasma capsulatum. AC, alveolar consolidation; M, alveolar
More informationCoccidioidomycosis in Rheumatologic Patients. Susan E. Hoover, MD
Coccidioidomycosis in Rheumatologic Patients Susan E. Hoover, MD The problem Prevalence of rheumatoid arthritis is 1% Population of Arizona is 6 million At least 150,000 new cocci infections yearly DMARDs
More informationHawai i to Zero. Timothy McCormick Harm Reduction Services Branch Hawai i Department of Health. January 16, 2018
HIV Prevention Efforts in Hawai i Hawai i to Zero Timothy McCormick Harm Reduction Services Branch Hawai i Department of Health January 16, 2018 People living with HIV who take HIV medicine as prescribed
More informationLUNG FUNGUS PRESENTED WITH NODULES- A CASE REPORT
LUNG FUNGUS PRESENTED WITH NODULES- A CASE REPORT Dr Ujwal Thakur 1, Prof. Dr Huang Jinbai 2 and Prof. Dr Ren Boxu 3 1Department of radiology, the first affiliated Hospital of Yangtze University, Jingzhou,
More informationPrevalence of Self-Reported Obesity Among U.S. Adults by State and Territory. Definitions Obesity: Body Mass Index (BMI) of 30 or higher.
Prevalence of Self-Reported Obesity Among U.S. Adults by State and Territory Definitions Obesity: Body Mass Index (BMI) of 30 or higher. Body Mass Index (BMI): A measure of an adult s weight in relation
More informationInfectious Diseases-HAI, Infectious Diseases Arizona Department of Health Services, Public Health Services. Phoenix, Arizona. Assignment Description
Infectious Diseases-HAI, Infectious Diseases Arizona Department of Health Services, Public Health Services Phoenix, Arizona Assignment Description The Fellow will be situated in the the Office of Infectious
More informationIsolation Precautions in Clinics
Purpose Audience General principles Possible Exposures To define isolation precautions in a clinic setting. Clinics Isolation status should be determined primarily by the suspected disease and/or pathogen.
More informationPRIMARY IMMUNODEFICIENCY DISEASES 3RD EDITION FREE
page 1 / 5 page 2 / 5 primary immunodeficiency diseases 3rd pdf Primary Immunodeficiency Diseases presents discussions of gene identification, mutation detection, and clinical and research applications
More informationUsing Hospitalization Data To Estimate The Public Health Burden of Coccidioidomycosis in California
Using Hospitalization Data To Estimate The Public Health Burden of Coccidioidomycosis in California V. Flaherman, R. Hector, G. Rutherford University of California, San Francisco Valley Fever Vaccine Project
More informationObesity Trends:
Obesity Trends: 1985-2014 Compiled by the Centers for Disease Control and Prevention Retrieved from http://www.cdc.gov/obesity/data/prevalencemaps.html Organized into two groupings due to methodological
More informationChronic pulmonary aspergillosis diagnosis and management in resource-limited setting
Chronic pulmonary aspergillosis diagnosis and management in resource-limited setting Professor Retno Wahyuningsih Professor of Medical Mycology Department of Parasitology, Faculty of Medicine Universitas
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationSee this link for more details on Flu and ILI activity, including charts, graphs and maps:
Influenza (FLU) Update for Week #02 Week Ending 1-12-19 The CDC reported that Influenza (Flu) activity, which includes diagnosed flu as well as ILI (Influenza-Like- Illness), remained elevated. The percentage
More informationFungal Infections. Alessandro Diana November 22th 2007
Fungal Infections Alessandro Diana November 22th 2007 alessandro.diana@ne.ch Topics Aspergillosis Candidiasis Cryptococcosis Histoplasmosis Coccidioidomycosis Blastomyocosis Sporotrichosis Pneumocystis
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationSwine Influenza Update #3. Triage, Assessment, and Care of Patients Presenting with Respiratory Symptoms
Updated 12:00 p.m. April 30, 2009 Swine Influenza Update #3 Introduction: This document revises our last update which was sent April 28 th, 2009. The most important revisions include the following: 1.
More informationSeroprevalence of Babesia microti in Individuals with Lyme Disease. Sabino R. Curcio, M.S, MLS(ASCP)
Seroprevalence of Babesia microti in Individuals with Lyme Disease Sabino R. Curcio, M.S, MLS(ASCP) Lyme Disease Most common vectorborne illness in the United States Caused by the tick-transmitted spirochete
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationEpidemiologic, Clinical, and Diagnostic Aspects of Coccidioidomycosis
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 26 30 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.02230-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Epidemiologic,
More informationJudith A. Aberg, MD; Linda M. Mundy, MD; and William G. Powderly, MD
Pulmonary Cryptococcosis in Patients Without HIV Infection* Judith A. Aberg, MD; Linda M. Mundy, MD; and William G. Powderly, MD Purpose: To further elucidate the diagnostic and therapeutic approaches
More informationTuberculosis Pathogenesis
Tuberculosis Pathogenesis Renuka Khurana, MD, MPH May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Renuka Khurana, MD, MPH has the following disclosures
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Tuberculosis Pathogenesis Lynn Horvath, MD April 3, 2012 Lynn Horvath, MD has the following disclosures to make: No conflict of interests No relevant
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationRespiratory Diseases and Disorders
Chapter 9 Respiratory Diseases and Disorders Anatomy and Physiology Chest, lungs, and conducting airways Two parts: Upper respiratory system consists of nose, mouth, sinuses, pharynx, and larynx Lower
More informationInfluenza (FLU) Update for Week #52 Week Ending
Influenza (FLU) Update for Week #52 Week Ending 12-29-18 For week #52 (ending 12-29-18) the CDC reported that influenza (Flu) activity, which includes diagnosed flu as well as ILI (Influenza-Like-Illness),
More informationViral Hemorrhagic Fevers CDC, AFIP
CDC, AFIP Diverse group of illnesses caused by RNA viruses from 4 families: Arenaviridae, Bunyaviridae, Filoviridae, Flaviridae Differ by geographic occurrence and vector/reservoir Share certain clinical
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationUphill both ways: Fatigue and quality of life in valley fever
Medical Mycology, 2016, 54, 310 317 doi: 10.1093/mmy/myv097 Advance Access Publication Date: 26 November 2015 Original Article Original Article Uphill both ways: Fatigue and quality of life in valley fever
More informationHEALTH ADVISORY: MEASLES EXPOSURES IN NEW YORK STATE
December 11, 2018 To: Health Care Providers, Hospitals, Emergency Departments, Dental Providers, and Local Health Departments From: New York State Department of Health, Bureau of Immunization HEALTH ADVISORY:
More informationElements for a Public Summary. [Product Name] 40 mg/ml oral suspension. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary [Product Name] 40 mg/ml oral suspension VI.2.1 Overview of disease epidemiology Fungi (yeasts) are small organisms that feed by breaking down tissue. In humans, fungi
More information2018 HPV Legislative Report Card
2018 HPV Legislative Report Card This report card is a snapshot of each state s documented efforts to enact or introduce HPV vaccine legislation to improve education and awareness, or provide access to
More informationWhat is Zika virus? What are the symptoms and complications of Zika virus infection? Are cases expected in Canada?
What is Zika virus? Zika Virus Update for Healthcare Professionals Updated June 22, 2016; italicized text indicates clarification of wording contained in previous versions. Zika virus is a Flavivirus transmitted
More informationInfectious Disease Control Oi Orientation. Providence Health & Services
Infectious Disease Control Oi Orientation ti Providence Health & Services Infection Control Who is at risk of infection & why? Exposures and Outcomes What tools do we use to reduce risk? Surveillance Analysis
More informationA rash case Infection control management of measles
A rash case Infection control management of measles 23 th June 2013 PanCeltic Meeting Dr Jo Hargreaves Microbiology SpR University Hospital of Wales, Cardiff Acknowledgements Dr Harriet Hughes Nicola Bevan,
More informationTitle Coccidioidomycosis (Valley fever) case data for the southwestern United States
Open Health Data: 1. Overview Title Coccidioidomycosis (Valley fever) case data for the southwestern United States Paper Authors 1. Gorris, Morgan E.; (Lead/corresponding author) 2. Cat, Linh A.; 3. Matlock,
More informationInteresting cases in fungal asthma
Interesting cases in fungal asthma Ritesh Agarwal MD, DM Professor of Pulmonary Medicine Postgraduate Institute of Medical Education and Research Chandigarh, India Fungal asthma Broadly defined as the
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationA Patient s Guide to Lyme Disease
A Patient s Guide to Lyme Disease Suite 11-13/14/15 Mount Elizabeth Medical Center 3 Mount Elizabeth Singapore, 228510 Phone: (65) 6738 2628 Fax: (65) 6738 2629 DISCLAIMER: The information in this booklet
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationInfection Prevention Prevention and Contr
Infection Prevention and Control o What is an infection? An infection is an illness caused by microorganisms A disease producing micro organism is called a pathogen Most microorganisms are classified as:
More information